BioVaxys Technology Corp. Closes Debt Settlement Transaction

Executive Summary

• BioVaxys Technology Corp. issued 1,792,387 common shares at a deemed value of $0.23 per share to settle accrued indebtedness totaling $412,249.
• The settlement fully resolves the outstanding debt and represents a financing transaction rather than a routine administrative action.
• All issued securities are subject to a four‑month statutory hold period under applicable securities legislation.

Key Details

• Settlement Shares Issued: 1,792,387 common shares.
• Deemed Value per Share: $0.23.
• Total Debt Settled: $412,249 (accrued and outstanding indebtedness).
• Transaction Type: Full and final settlement of debt via equity issuance (non‑cash financing).
• Statutory Hold Period: Four months from the date of issuance, per securities legislation.
• Regulatory Notice: The release does not constitute an offer or solicitation in the United States; shares are not registered under the U.S. Securities Act.

Notable Quotes

• “The issuance of Settlement Shares resolves our outstanding indebtedness and positions BioVaxys to continue focusing on advancing our clinical‑stage immunotherapy programs.” – James Passin, Chief Executive Officer

This release excludes boilerplate company description, forward‑looking disclaimer language, and distribution footers.